Bladder Cancer - Results from #460

REVIEW UroToday

Organ preservation in muscle-invasive urothelial bladder cancer. April 8, 2024

Open radical cystectomy in England: the current standard of care - an analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit and Hospital Episodes Statistics (HES) data. April 7, 2024

Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. April 7, 2024

The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma. April 6, 2024

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. April 6, 2024

Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. April 6, 2024

Late urinary toxicity and QOL with pelvic radiotherapy for high-risk prostate cancer: Dose-effect relations in the POP-RT randomized phase III trial. April 5, 2024

Strategies for Overcoming Immune Evasion in Bladder Cancer. April 5, 2024

Incidence rates of bladder and kidney cancers among US military servicemen: comparison with the rates in the general US population. April 5, 2024

Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments. April 5, 2024

Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer. April 5, 2024

Diagnostic Accuracy of F-18 FDG PET/CT for Preoperative Lymph Node Staging in Newly Diagnosed Bladder Cancer Patients: A Systematic Review and Meta-Analysis. April 5, 2024

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. April 5, 2024

Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. April 5, 2024

Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer. April 5, 2024

Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer. April 5, 2024

Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer. April 4, 2024

NPEPPS Is a Druggable Driver of Platinum Resistance. April 4, 2024

Antibody-Drug Conjugate Combination Therapy in Patients with Metastatic Urothelial Cancer - Expert Commentary April 3, 2024

The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma April 3, 2024

Page 24 of 517